BridgeMD
New treatment option for Pulmonary Embolism
Official title Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)
ClinicalTrials.gov ID: NCT06372730
What this study is testing
- What it's testing
- Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients ≥ 18 years,
- who experienced an objectively proven PE,
- who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be...
You likely can't join if
- Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)
- Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and...
- No Social security affiliation
- Isolated DVT
- Pregnant women and parturients
- Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)
See the full eligibility criteria
- Patients ≥ 18 years,
- who experienced an objectively proven PE,
- who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.
- Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)
- Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8...
- No Social security affiliation
- Isolated DVT
- Pregnant women and parturients
- Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)
- Life expectancy \< 6 months
- Any patients for whom there is a strong indication to treat longer than 6 months:
- PE provoked by a major persistent factor (e.g. cancer)
- Recurrent unprovoked PE PE provoked by a major transient risk factor (e.g. surgery with general anesthesia for greater than 30 min, confined to bed in hospital for at least 3 days with an acute illness, cesarean...
- BMI ≥ 30
- Chronic respiratory disease
- Chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, etc.)
- Hepatocellular insufficiency
- Renal insufficiency with creatinine clearance \< 60 mL/min
- Chronic or persistent immobilization
The study team makes the final eligibility decision.
Where it's taking place
- Amiens, France, France
- Angers, France, France
- Brest, France, France
- Colombes, France, France
- La Roche-sur-Yon, France, France
- Le Kremlin-Bicêtre, France, France
- Les Sables-d'Olonne, France, France
- Paris, France, France
- Quimper, France, France
- Saint-Etienne, France, France
- Toulon, France, France
- Toulouse, France, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amiens, France, France; Angers, France, France; Brest, France, France; Colombes, France, France; La Roche-sur-Yon, France, France; Le Kremlin-Bicêtre, France, France and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.